THE US Food and Drug
Administration has granted
approval for Tresiba (insulin
degludec injection) and Ryzodeg
70/30 (insulin degludec/insulin
aspart injection) to improve glucose
control in adults with diabetes.
Tresiba is a long-acting once daily
insulin analog injection designed to
improve glycaemic control in adults
with type 1 and type 2 diabetes,
with dosing individualised based on
the patients’ needs.
Ryzodeg 70/30 is administered
once or twice daily in combination
with mealtime insulin.
Both medications are made by
Novo Nordisk.The above article was sent to subscribers in Pharmacy Daily's issue from 28 Sep 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Sep 15
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.